Verde Science Appoints Chief Technology Officer

Verde Science, Inc., (OTCQB-VRCI) a Medical Marijuana Research and Development Company, announces the expansion of its organization with the appointment of Manit Patel as Chief Technology Officer. According to Harp Sangha, Verde’s Chairman and CEO, “Mr. Patel brings an important array of pharmaceutical experience to Verde Science at this pivotal time when many significant R&D and business opportunities are moving forward. His considerable industry knowledge and expertise includes research and production, market research, and business development – all of which will help ensure the company optimizes the unfolding business opportunities.”

Manit Patel earned a Bachelor in Pharmaceutical Sciences from The Institute of Chemical Technology in Mumbai, India, and an MBA from Queensland University of Technology in Brisbane, Australia. He was Director of Business Development for Sterkem Group, a Mumbai, India based pharmaceutical R&D, production, and marketing firm. Subsequently, he was a market research manager for iData, an international market research consulting firm based in Vancouver, Canada. Mr. Patel has a broad network of international business contacts throughout the pharmaceutical sector, which will be an important resource for Verde Science as it moves forward with its growth plans.

About Verde Science, Inc. (VRCI)

Verde Science, Inc. is a public company trading under the symbol OTCQB-VRCI. The Company is focused on Medical Marijuana Research and Development, and providing advisory services, quality assurance, and aeroponic growing systems in the burgeoning Medical Marijuana industry to established, licensed growers throughout Canada.

Safe Harbor Statements

Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates”, “intends” or “believes”, or that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, or “be achieved”. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information please contact:

Harp Sangha, Chairman/CEO

Louis Silver, Director of Investor Relations

Posted in: Press

Comments are closed.